Market Overview

UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Vertex Pharmaceuticals

Related VRTX
Vertex Pharmaceuticals: Analysts Offer Insight On Business Developments
Should You Buy Vertex Pharmaceuticals (VRTX) Ahead of Earnings? - Tale of the Tape

In a report published Friday, Deutsche Bank reiterated its Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX), but lowered its price target from $77.00 to $75.00.

Deutsche Bank noted, “We rate VRTX shares Buy on the back of potential success in their CF program targeting the homozygous F508del patients with VX-809 & Kalydeco. Our model suggests no value being assigned to HCV, no value to other CF gating mutations, and about 35% chance of success on 508del population. We model $1.4B revs, $1.2B expenses in 2013. Key questions remain Incivek & expense guidance. We model '13 down Incivek -35% & every $100M impacts DCF by $1.5/sh. Maintain Buy.”

Vertex Pharmaceuticals closed on Thursday at $39.10.

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings

 

Related Articles (VRTX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters